Pharmacological targeting of the protein synthesis mTOR/4E‐BP1 pathway in cancer‐associated fibroblasts abrogates pancreatic tumour chemoresistance
Camille Duluc(Inserm), Corinne Bousquet(Centre National de la Recherche Scientifique), Marie‐Pierre Bousquet(Centre National de la Recherche Scientifique), Siham Moatassim-Billah(Mohammed V University), Florence Breibach(Pharmacochimie et Biologie pour le Développement), Aurélie Perraud(Centre Hospitalier Universitaire de Limoges), Marion Gayral(Inserm), Richard Tomasini(Centre de Recherche en Cancérologie de Marseille), Stéphane Pyronnet(Centre National de la Recherche Scientifique), Marie‐Bernadette Delisle(Inserm), Rémi Samain(Inserm), Pierre Cordelier(Centre National de la Recherche Scientifique), Herbert Schmid(Novartis (Switzerland)), Mounira Chalabi‐Dchar(Inserm), Yvan Martineau(Centre National de la Recherche Scientifique), Muriel Mathonnet(Inserm)
Cited by 196
Related Papers
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
|The Lancet Neurology|2022|651
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions
|Nature Communications|2017|403
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290